Kathy Miller
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kathy Miller sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Kathy Miller: 8 sponsored US clinical trials, 1 recruiting.
Kathy Miller sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Estrogen-receptor-low Breast Cancer, with 1 trials.
Upper-quartile sponsor footprint
Kathy Miller sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
NCT05846789
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT04134884
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NCT03243331
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
NCT02575339
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
NCT02595372
Impact of LOFT Therapy™ on Breast Cancer Survivors
NCT02491957
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
NCT02443103
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
NCT00827372
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Kathy Miller pipeline
1 recruiting of 8 indexed (13% open); 5 completed (63%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Estrogen-receptor-low Breast Cancer (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kathy Miller: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Kathy Miller sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Kathy Miller page
8 registered trials is a research-attention snapshot, not an endorsement of Kathy Miller or any single study.
- 1 of Kathy Miller's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Estrogen-receptor-low Breast Cancer is the condition Kathy Miller studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Estrogen-receptor-low Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kathy Miller pipeline card: 8 registered trials from official public datasets.Report a data error.